论文部分内容阅读
20多年来β受体阻滞剂在高血压的治疗中起着重要的作用,美国高血压指南(JNC6、7)将β受体阻滞剂作为高血压患者治疗的一线药物。近年来一些新的高血压循证试验将新的降压药物(长效CCB及ACEI和ARB)与传统的降压药物β受体阻滞剂(阿替洛尔、心得安)作对照,并进行长期治疗的终点事
For more than 20 years, beta-blockers have played an important role in the treatment of hypertension. The American Guideline for Hypertension (JNC6,7) uses beta-blockers as a first-line treatment for patients with hypertension. In recent years, some new hypertensive evidence-based trials will be the new antihypertensive drugs (long-acting CCB and ACEI and ARB) and the traditional antihypertensive drugs β-blockers (atenolol, propranolol) as a control and The end of long-term treatment